Integrated Filing — IndAS



General information about company

Scrip Code 544210
NSE Symbol EMCURE
MSEI Symbol NOTLISTED
ISIN INE168P01015
Name of company EMCURE PHARMACEUTICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 03-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 03-11-2026   12:48:00
End date and time of board meeting 03-11-2026   13:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 06-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.emcure.com/wp-content/uploads/2025/05/Related-Party-Transactions-Policy_Amendment-06.02.2025F.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There are no default in loans and Debt Securities by the Company as on reporting date



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 1,66,798.40 3,11,891.50
Other income 3,353.80 5,857.00
Total income 1,70,152.20 3,17,748.50
2 Expenses
(a) Cost of materials consumed 53,009.40 94,980.50
(b) Purchases of stock-in-trade 27,237.00 52,275.10
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (10,550.50) (14,232.00)
(d) Employee benefit expense 23,148.40 44,188.60
(e) Finance costs 3,242.00 6,519.60
(f) Depreciation, depletion and amortisation expense 6,501.00 12,817.60
(f) Other Expenses
1 Other expenses 36,362.30 65,882.20
2 Net (gain)/ loss on foreign currency transactions (2,035.00) (4,788.00)
Total other expenses 34,327.30 61,094.20
Total expenses 1,36,914.60 2,57,643.60
3 Total profit before exceptional items and tax 33,237.60 60,104.90
4 Exceptional items 0.00 0.00
5 Total profit before tax 33,237.60 60,104.90
6 Tax expense
7 Current tax 8,693.00 15,727.70
8 Deferred tax (298.20) (476.40)
9 Total tax expenses 8,394.80 15,251.30
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 24,842.80 44,853.60
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 24,842.80 44,853.60
17 Other comprehensive income net of taxes (11.20) (22.50)
18 Total Comprehensive Income for the period 24,831.60 44,831.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 18,971.10 18,971.10
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 13.1 23.65
Diluted earnings (loss) per share from continuing operations 13.08 23.62
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 13.1 23.65
Diluted earnings (loss) per share from continuing and discontinued operations 13.08 23.62
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) There are no default in loans and Debt Securities by the Company as on reporting date



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1,48,737.70
Capital work-in-progress 18,263.50
Investment property 0.00
Goodwill 0.00
Other intangible assets 1,847.80
Intangible assets under development 1,138.90
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 1,65,773.40
Trade receivables, non-current 0.00
Loans, non-current 35,219.40
Other non-current financial assets
1 Other non-current financial assets 2,120.50
Total of other non-current financial assets 2,120.50
Total non-current financial assets 2,03,113.30
Deferred tax assets (net) 72.00
Other non-current assets
1 Income tax assets (net) 4,728.50
2 Other non-current assets 6,344.50
3 Right-of-use assets 27,097.30
Total of other non-current assets 38,170.30
Total non-current assets 4,11,343.50
2 Current assets
Inventories 1,38,989.60
Current financial asset
Current investments 0.00
Trade receivables, current 1,72,396.00
Cash and cash equivalents 1,639.30
Bank balance other than cash and cash equivalents 550.30
Loans, current 204.60
Other current financial assets
Total of other current financial assets 9,605.30
Total current financial assets 1,84,395.50
Current tax assets (net) 0.00
Other current assets
1 Other current assets 19,934.60
Total of other current assets 19,934.60
Total current assets 3,43,319.70
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 7,54,663.20
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 18,971.10
Other equity 3,91,655.20
Total equity attributable to owners of parent 4,10,626.30
Non controlling interest
Total equity 4,10,626.30
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 71,983.80
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 3,824.50
Total of other non-current financial liabilities 3,824.50
Total non-current financial liabilities 75,808.30
Provisions, non-current 2,839.40
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Lease Liabilities 19,170.70
Total of other non-current liabilities 19,170.70
Total non-current liabilities 97,818.40
Current liabilities
Current financial liabilities
Borrowings, current 71,148.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 5,224.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,21,512.60
Total Trade payable 1,26,736.60
Other current financial liabilities
1 Other current financial liabilities 25,921.50
Total of other current financial liabilities 25,921.50
Total current financial liabilities 2,23,806.10
Other current liabilities 9,415.50
1 Other current liabilities 6,343.00
2 Lease Liabilities 3,072.50
Total of other current liabilities 9,415.50
Provisions, current 5,492.70
Current tax liabilities (Net) 7,504.20
Deferred government grants, Current 0.00
Total current liabilities 2,46,218.50
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,44,036.90
Total equity and liabilites 7,54,663.20
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) There are no default in loans and Debt Securities by the Company as on reporting date



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Other comprehensive income/ (loss) for the period / year (15.00) (30.00)
Total Amount of items that will not be reclassified to profit and loss (15.00) (30.00)
2 Income tax relating to items that will not be reclassified to profit or loss (3.80) (7.50)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (11.20) (22.50)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 60,104.90
Adjustments for reconcile profit (loss)
Adjustments for finance costs 6,519.60
Adjustments for decrease (increase) in inventories (18,320.00)
Adjustments for decrease (increase) in trade receivables, current (18,909.40)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,971.80)
Adjustments for decrease (increase) in other non-current assets 13.30
Adjustments for other financial assets, non-current 102.00
Adjustments for other financial assets, current 707.70
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 12,702.10
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 3,850.80
Adjustments for depreciation and amortisation expense 12,817.60
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 862.30
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 916.70
Adjustments for other financial liabilities, non-current 9.90
Adjustments for unrealised foreign exchange losses gains 9.80
Adjustments for dividend income 802.20
Adjustments for interest income 1,477.50
Adjustments for share-based payments 315.50
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (85.60)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (2,739.20)
Net cash flows from (used in) operations 57,365.70
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 17,536.80
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 39,828.90
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 141.50
Purchase of property, plant and equipment 17,552.00
Proceeds from sales of investment property 9,001.70
Purchase of investment property 32,345.20
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 126.20
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 14,893.00
Cash receipts from repayment of advances and loans made to other parties 21,655.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 802.20
Interest received 1,252.40
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (32,063.60)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 1,152.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 30,022.20
Repayments of borrowings 21,572.10
Payments of lease liabilities 2,384.60
Dividends paid 6,829.20
Interest paid 4,995.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (4,606.70)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 3,158.60
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (17.20)
Net increase (decrease) in cash and cash equivalents 3,141.40
Cash and cash equivalents cash flow statement at beginning of period (1,502.10)
Cash and cash equivalents cash flow statement at end of period 1,639.30





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Purchase of goods or services 3,000.00 Approved 252.90 (37.50) (38.60)
2 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Purchase of goods or services 20,000.00 Approved 5,185.30 (951.10) (611.80)
3 Emcure Pharmaceuticals Limited Uth Beverages Factory Pvt. Ltd. Enterprise over which Key Management Personnel have control Purchase of goods or services 1,000.00 Approved 43.90 10.80 (1.90)
4 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Sale of fixed assets 1,000.00 Approved 2.60 0.00 0.00
5 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Sale of goods or services 6,000.00 Approved 1,402.10 0.00 537.60
6 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Sale of goods or services 10,000.00 Approved 4,197.30 1,688.80 3,230.90
7 Emcure Pharmaceuticals Limited Emcure Lifesciences Private Limited Subsidiaries Sale of goods or services 13,200.00 Approved 1,526.80 0.00 1,435.80
8 Emcure Pharmaceuticals Limited Tillomed Laboratories Limited Holding-Subsidiary Sale of goods or services 71,500.00 Approved 17,580.40 (9,722.10) 1,201.70
9 Emcure Pharmaceuticals Limited Tillomed Malta Limited Subsidiaries Sale of goods or services 50,000.00 Approved 15,821.70 16,951.80 24,295.40
10 Emcure Pharmaceuticals Limited Tillomed Italia S.R.L, Italy Subsidiaries Sale of goods or services 20,000.00 Approved 11,088.00 15,177.60 14,861.80
11 Emcure Pharmaceuticals Limited Marcan Pharmaceuticals Inc. Subsidiaries Sale of goods or services 51,500.00 Approved 15,953.10 (588.20) 1,304.70
12 Emcure Pharmaceuticals Limited Emcure Pharmaceuticals South Africa (Pty) Ltd Subsidiaries Sale of goods or services 60,000.00 Approved 17,604.40 15,107.50 8,087.90
13 Emcure Pharmaceuticals Limited Emcure Pharmaceuticals Mena FZ-LLC. Subsidiaries Sale of goods or services 20,000.00 Approved 1,054.30 1,991.10 536.70
14 Emcure Pharmaceuticals Limited Emcure Pharma Peru S.A.C. Subsidiaries Sale of goods or services 5,400.00 Approved 931.40 5,487.80 5,615.50
15 Emcure Pharmaceuticals Limited Emcure Pharma Chile SpA Subsidiaries Sale of goods or services 7,500.00 Approved 1,499.80 5,765.00 4,638.00
16 Emcure Pharmaceuticals Limited Lazor Pharmaceuticals Limited Subsidiaries Sale of goods or services 5,000.00 Approved 658.70 973.70 1,223.60
17 Emcure Pharmaceuticals Limited Emcure Pharma Philippines Inc Subsidiaries Sale of goods or services 2,000.00 Approved 225.60 386.30 581.80
18 Emcure Pharmaceuticals Limited Avet Lifesciences Private Limited Enterprise over which Key Management Personnel have control Sale of goods or services 50,000.00 Approved 13,117.00 16,674.60 24,083.90
19 Emcure Pharmaceuticals Limited Heritage Pharma Labs Inc. Enterprise over which Key Management Personnel have control Sale of goods or services 8,500.00 Approved 813.80 480.50 753.60
20 Emcure Pharmaceuticals Limited Heritage Pharmaceuticals Inc. Enterprise over which Key Management Personnel have control Sale of goods or services 8,500.00 Approved 2,557.70 1,954.70 2,382.80
21 Emcure Pharmaceuticals Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have control Sale of goods or services 2,500.00 Approved 185.80 70.60 168.90
22 Emcure Pharmaceuticals Limited Emcure Pharma Mexico S.A. DE C.V. Subsidiaries Sale of goods or services 1,800.00 Approved 119.00 49.60 174.40
23 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Investment 0.00 Not applicable 32.10 0.00 0.00
24 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Investment 0.00 Not applicable 36.10 0.00 0.00
25 Emcure Pharmaceuticals Limited Emcutix Biopharmaceuticals Limited Subsidiaries Investment 0.00 Not applicable 3.00 0.00 0.00
26 Emcure Pharmaceuticals Limited Marcan Pharmaceuticals Inc. Subsidiaries Investment 0.00 Not applicable 0.90 0.00 0.00
27 Emcure Pharmaceuticals Limited Tillomed Laboratories Limited Holding-Subsidiary Investment 0.00 Not applicable 25.40 0.00 0.00
28 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Inter-corporate deposit 40,000.00 Approved 12,498.00 35,564.00 28,662.00 Inter-corporate deposit 7.500 36 Unsecured General Purpose
29 Emcure Pharmaceuticals Limited Emcutix Biopharmaceuticals Limited Subsidiaries Inter-corporate deposit 10,000.00 Approved 1,105.00 2,804.00 3,269.00 Inter-corporate deposit 7.500 36 Unsecured General Purpose
30 Emcure Pharmaceuticals Limited Emcure Wellness Private Limited Subsidiaries Inter-corporate deposit 10,000.00 Approved 175.00 265.00 440.00 Inter-corporate deposit 7.500 36 Unsecured General Purpose
31 Emcure Pharmaceuticals Limited Emcure Lifesciences Private Limited Subsidiaries Inter-corporate deposit 10,000.00 Approved 1,115.00 500.00 0.00 Inter-corporate deposit 7.500 36 Unsecured General Purpose
32 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Inter-corporate deposit 0.00 Not applicable 19,400.00 0.00 0.00
33 Emcure Pharmaceuticals Limited Emcutix Biopharmaceuticals Limited Subsidiaries Inter-corporate deposit 0.00 Not applicable 640.00 0.00 0.00
34 Emcure Pharmaceuticals Limited Emcure Lifesciences Private Limited Subsidiaries Inter-corporate deposit 0.00 Not applicable 1,615.00 0.00 0.00
35 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Inter-corporate deposit 60,000.00 Approved 27,003.00 (55,720.00) (65,525.00) Inter-corporate deposit 7.500 36 Unsecured General Purpose
36 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Inter-corporate deposit 0.00 Not applicable 17,198.00 0.00 0.00 Inter-corporate deposit 7.500 36 Unsecured General Purpose
37 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Interest received 3,200.00 Approved 1,293.80 0.00 155.60
38 Emcure Pharmaceuticals Limited Emcutix Biopharmaceuticals Limited Subsidiaries Interest received 800.00 Approved 123.00 0.00 37.20
39 Emcure Pharmaceuticals Limited Emcure Wellness Private Limited Subsidiaries Interest received 1,000.00 Approved 15.10 0.00 5.00
40 Emcure Pharmaceuticals Limited Emcure Lifesciences Private Limited Subsidiaries Interest received 1,000.00 Approved 20.70 0.00 6.80
41 Emcure Pharmaceuticals Limited Emcure Pharma Philippines Inc Subsidiaries Interest received 0.00 Not applicable 20.50 108.40 130.20
42 Emcure Pharmaceuticals Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have control Interest paid 0.00 Not applicable 3.80 (1.70) (1.70)
43 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Interest paid 5,000.00 Approved 2,289.50 0.00 (718.90)
44 Emcure Pharmaceuticals Limited Mr. Satish Mehta Promoters Remuneration 6,000.00 Approved 1,709.70 (1,113.80) (613.80)
45 Emcure Pharmaceuticals Limited Mr. Sunil Mehta Promoters Remuneration 6,000.00 Approved 274.50 (58.30) (58.30)
46 Emcure Pharmaceuticals Limited Mrs. Namita Thapar Promoters Remuneration 6,000.00 Approved 274.50 (57.80) (57.80)
47 Emcure Pharmaceuticals Limited Mr. Samit Mehta Promoters Remuneration 6,000.00 Approved 193.90 (38.50) (38.50)
48 Emcure Pharmaceuticals Limited Mr. Vikas Thapar Promoters Group Remuneration 6,000.00 Approved 274.50 (57.80) (57.80)
49 Emcure Pharmaceuticals Limited Mr. Sanjay Mehta Promoter Group Remuneration 6,000.00 Approved 274.50 (58.30) (58.30)
50 Emcure Pharmaceuticals Limited Mr. Rutav Mehta Promoter Group Remuneration 6,000.00 Approved 32.00 (6.00) (6.00)
51 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Any other transaction Laboratory Service Income 50.00 Approved 0.30 0.30 0.20
52 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Any other transaction Laboratory Service Income 200.00 Approved 1.00 0.00 0.10
53 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Any other transaction Trade / Security deposits accepted 0.00 Not applicable 9.90 (541.10) (551.00)
54 Emcure Pharmaceuticals Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have control Any other transaction Commission expenses 1,000.00 Approved 162.20 (63.50) (77.00)
55 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Any other transaction Reimbursement of expenses made 0.00 Not applicable 29.20 (20.20) (7.80)
56 Emcure Pharmaceuticals Limited Marcan Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement of expenses made 0.00 Not applicable 158.60 (186.70) (344.50)
57 Emcure Pharmaceuticals Limited Mantra Pharma Inc Holding-Subsidiary Any other transaction Reimbursement of expenses made 0.00 Not applicable 2.70 0.00 (2.70)
58 Emcure Pharmaceuticals Limited Avet Lifesciences Private Limited Enterprise over which Key Management Personnel have control Any other transaction Reimbursement of expenses made 0.00 Not applicable 219.80 0.00 0.00
59 Emcure Pharmaceuticals Limited H.M. Sales Corporation Subsidiaries Any other transaction Reimbursement of expenses made 0.00 Not applicable 0.30 (0.30) 0.00
60 Emcure Pharmaceuticals Limited Uth Beverages Factory Pvt. Ltd. Enterprise over which Key Management Personnel have control Any other transaction Reimbursement of expenses made 0.00 Not applicable 6.20 (0.80) 0.00
61 Emcure Pharmaceuticals Limited Tillomed Italia S.R.L, Italy Subsidiaries Any other transaction Reimbursement of expenses made 0.00 Not applicable 4.40 0.00 (4.40)
62 Emcure Pharmaceuticals Limited Tillomed Malta Limited Subsidiaries Any other transaction Reimbursement of expenses made 0.00 Not applicable 20.30 (17.80) (38.30)
63 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Any other transaction Reimbursement of expenses received 0.00 Not applicable 111.90 282.60 73.10
64 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Any other transaction Reimbursement of expenses received 0.00 Not applicable 90.00 87.00 32.40
65 Emcure Pharmaceuticals Limited Emcutix Biopharmaceuticals Limited Subsidiaries Any other transaction Reimbursement of expenses received 0.00 Not applicable 1.80 6.20 8.30
66 Emcure Pharmaceuticals Limited Emcure Wellness Private Limited Subsidiaries Any other transaction Reimbursement of expenses received 0.00 Not applicable 0.90 1.30 2.30
67 Emcure Pharmaceuticals Limited Tillomed Laboratories Limited Subsidiaries Any other transaction Reimbursement of expenses received 0.00 Not applicable 247.10 1,120.90 1,393.20
68 Emcure Pharmaceuticals Limited Tillomed Malta Limited Subsidiaries Any other transaction Reimbursement of expenses received 0.00 Not applicable 8.80 20.40 4.20
69 Emcure Pharmaceuticals Limited Marcan Pharmaceuticals Inc. Subsidiaries Any other transaction Reimbursement of expenses received 0.00 Not applicable 42.90 61.30 104.30
70 Emcure Pharmaceuticals Limited Mantra Pharma Inc Holding-Subsidiary Any other transaction Reimbursement of expenses received 0.00 Not applicable 5.30 78.40 0.00
71 Emcure Pharmaceuticals Limited Heritage Pharmaceuticals Inc. Enterprise over which Key Management Personnel have control Any other transaction Reimbursement of expenses received 0.00 Not applicable 16.60 52.10 16.70
72 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Any other transaction Rent income 3,000.00 Approved 882.60 892.20 479.20
73 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Any other transaction Rent income 300.00 Approved 30.00 0.00 5.80
74 Emcure Pharmaceuticals Limited Emcutix Biopharmaceuticals Limited Subsidiaries Any other transaction Rent income 100.00 Approved 5.90 2.20 8.60
75 Emcure Pharmaceuticals Limited Emcure Wellness Private Limited Subsidiaries Any other transaction Rent income 600.00 Approved 4.10 1.50 5.90
76 Emcure Pharmaceuticals Limited Emcure Lifesciences Private Limited Subsidiaries Any other transaction Rent income 600.00 Approved 0.20 0.10 0.30
77 Emcure Pharmaceuticals Limited Incredible Ventures Private Limited Subsidiaries Any other transaction Rent income 50.00 Approved 0.20 0.00 0.00
78 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Any other transaction Financial guarantee fees charged 300.00 Approved 90.50 90.30 106.80
79 Emcure Pharmaceuticals Limited Tillomed Laboratories Limited Holding-Subsidiary Any other transaction Financial guarantee fees charged 500.00 Approved 104.70 124.40 230.40
80 Emcure Pharmaceuticals Limited Mantra Pharma Inc Holding-Subsidiary Any other transaction Financial guarantee fees charged 1,200.00 Approved 84.80 80.50 0.00
81 Emcure Pharmaceuticals Limited Emcure Pharmaceuticals Mena FZ-LLC. Subsidiaries Any other transaction Financial guarantee fees charged 240.00 Approved 15.60 14.20 25.00
82 Emcure Pharmaceuticals Limited Emcure Pharma Philippines Inc Subsidiaries Any other transaction Financial guarantee fees charged 240.00 Approved 8.00 12.20 20.60
83 Emcure Pharmaceuticals Limited Emcure Pharma Chile SpA Subsidiaries Any other transaction Financial guarantee fees charged 240.00 Approved 15.60 47.20 64.70
84 Emcure Pharmaceuticals Limited Tillomed Italia S.R.L, Italy Subsidiaries Any other transaction Financial guarantee fees charged 200.00 Approved 48.30 27.60 75.70
85 Emcure Pharmaceuticals Limited Emcure Pharmaceuticals Mena FZ-LLC. Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 6,000.00 Approved 108.50 (1,404.90) (1,562.80)
86 Emcure Pharmaceuticals Limited Emcure Nigeria Limited Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 600.00 Approved 20.60 (143.40) (130.80)
87 Emcure Pharmaceuticals Limited Emcure Pharma Mexico S.A. DE C.V. Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 2,400.00 Approved 393.40 (292.60) (317.90)
88 Emcure Pharmaceuticals Limited Emcure Brasil Farmaceutica Ltda. Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 1,200.00 Approved 15.30 (163.70) (158.90)
89 Emcure Pharmaceuticals Limited Emcure Pharmaceuticals Pty Ltd. Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 1,200.00 Approved 129.20 (268.20) (265.90)
90 Emcure Pharmaceuticals Limited Emcure Pharma Philippines Inc Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 1,000.00 Approved 114.20 (109.40) (114.20)
91 Emcure Pharmaceuticals Limited Emcure Pharmaceuticals South Africa (Pty) Ltd Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 5,000.00 Approved 1,683.80 0.00 (1,684.30)
92 Emcure Pharmaceuticals Limited Emcure Pharmaceuticals Dominicana, S.A.S Subsidiaries Any other transaction Marketing Support Fees (classified under Advertisement & Promotional Material) 900.00 Approved 66.40 0.00 (66.40)
93 Emcure Pharmaceuticals Limited Marcan Pharmaceuticals Inc. Subsidiaries Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 1,500.00 Approved 527.70 161.40 693.60
94 Emcure Pharmaceuticals Limited Tillomed Laboratories Limited Subsidiaries Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 3,000.00 Approved 1,099.10 1,791.40 2,945.20
95 Emcure Pharmaceuticals Limited Gennova Biopharmaceuticals Limited Subsidiaries Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 1,200.00 Approved 10.70 13.40 12.50
96 Emcure Pharmaceuticals Limited Emcutix Biopharmaceuticals Limited Subsidiaries Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 600.00 Approved 4.00 4.50 9.10
97 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 1,000.00 Approved 25.20 0.00 29.30
98 Emcure Pharmaceuticals Limited Emcure Lifesciences Private Limited Subsidiaries Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 600.00 Approved 1.40 0.00 1.60
99 Emcure Pharmaceuticals Limited Emcure Wellness Private Limited Subsidiaries Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 600.00 Approved 0.80 0.00 0.90
100 Emcure Pharmaceuticals Limited Mantra Pharma Inc Holding-Subsidiary Any other transaction Corporate Overhead Cross Charge (Income) (classified under other income) 1,200.00 Approved 108.90 145.60 18.30
101 Emcure Pharmaceuticals Limited Zuventus Healthcare Limited Subsidiaries Any other transaction Rent expense 100.00 Approved 16.20 (5.80) (2.90)
102 Emcure Pharmaceuticals Limited Mr. Sunil Mehta Promoters Any other transaction Rent expense 50.00 Approved 1.90 0.00 0.00
103 Emcure Pharmaceuticals Limited Mr. Sanjay Mehta Promoters Group Any other transaction Rent expense 50.00 Approved 1.90 0.00 0.00
104 Emcure Pharmaceuticals Limited Mrs. Bhavana Mehta Promoters Group Any other transaction Rent expense 50.00 Approved 0.40 0.00 0.00
105 Gennova Biopharmaceuticals Limited H.M. Sales Corporation Director and relative of Director are partner Sale of goods or services 1,050.00 Approved 32.00 0.40 30.60
106 Gennova Biopharmaceuticals Limited H.M. Sales Corporation Director and relative of Director are partner Any other transaction Commission expenses 1,250.00 Approved 17.00 5.50 8.10
107 Gennova Biopharmaceuticals Limited Mr. Samit Mehta Promoters Remuneration 87.50 Approved 87.50 18.60 0.00
108 Gennova Biopharmaceuticals Limited Dr. Rohan Gurjar Relative of Director Remuneration 19.70 Approved 19.70 0.00 0.00
109 Zuventus Healthcare Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have significant influence Sale of goods or services 300.00 Approved (162.00) 487.60 317.30
110 Zuventus Healthcare Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have significant influence Any other transaction Commission expenses 300.00 Approved 52.90 21.20 27.10
111 Zuventus Healthcare Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have significant influence Any other transaction Reimbursement of expenses made 0.00 Not applicable 0.00 0.00 0.00
112 Emcutix Biopharmaceuticals Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have significant influence Sale of goods or services 2,200.00 Approved 288.00 44.80 356.40
113 Emcutix Biopharmaceuticals Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have significant influence Interest paid 0.00 Not applicable 1.30 0.60 0.60
114 Emcutix Biopharmaceuticals Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have significant influence Any other transaction Trade/Security deposit accepted 0.00 Not applicable 0.00 35.00 0.00
115 Emcutix Biopharmaceuticals Limited H.M. Sales Corporation Enterprise over which Key Management Personnel have significant influence Any other transaction Commission expenses 1,320.00 Approved 2.80 0.00 1.20
116 Gennova Biopharmaceuticals Limited Rutav Mehta Promoter Group Remuneration Acquisition of shares 9.60 Approved 9.60 0.00 0.00
117 Emcure Pharmaceuticals Limited Mr. Satish Mehta Promoters Any other transaction Acquisition of shares 0.00 Not applicable 23.10 0.00 0.00
118 Emcure Pharmaceuticals Limited Mr. Sunil Mehta Promoters Any other transaction Acquisition of shares 0.00 Not applicable 24.10 0.00 0.00
119 Emcure Pharmaceuticals Limited Mr. Samit Mehta Promoters Any other transaction Acquisition of shares 0.00 Not applicable 8.00 0.00 0.00
120 Emcure Pharmaceuticals Limited Mrs. Bhavana Mehta Promoter Group Any other transaction Acquisition of shares 0.00 Not applicable 8.00 0.00 0.00
121 Emcure Pharmaceuticals Limited Mr. Sanjay Mehta Promoter Group Any other transaction Acquisition of shares 0.00 Not applicable 24.10 0.00 0.00
122 Emcure Pharmaceuticals Limited Torrent Urja 37 Private limited Associate company Investment 0.00 Not applicable 111.60 0.00 0.00
123 Emcure Pharmaceuticals Limited Torrent Urja 37 Private limited Associate company Purchase of goods or services 1,000.00 Not applicable 117.60 0.00 0.00
124 Emcure Pharmaceuticals Limited Sunsure Solarpark Twelve Private Lim Associate company Purchase of goods or services 1,500.00 Not applicable 445.60 0.00 0.00
Total value of transaction during the reporting period 2,07,339.30